Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Kymera Therapeutics (KYMR) Stock Price & Analysis
181 Followers
KYMR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.60 - $48.70
Previous Close$48.49
Volume948.61K
Average Volume (3M)612.81K
Market Cap
$2.98B
Enterprise Value$2.69B
Total Cash (Recent Filing)$374.88M
Total Debt (Recent Filing)$84.67M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Aug 02, 2024EPS Estimate
-$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding61,358,262
10 Day Avg. Volume608,349
30 Day Avg. Volume612,807
Standard Deviation0.25
R-Squared0.21
Alpha0.00525
Financial Highlights & Ratios
Price to Book (P/B)4.97
Price to Sales (P/S)24.98
Price to Cash Flow (P/CF)61.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue34.16
Enterprise Value/Gross Profit34.16
Enterprise Value/Ebitda-18.74
Forecast
1Y Price Target
$42.78Price Target Upside-8.67% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Kymera Therapeutics News
PremiumCompany Announcements
Kymera Therapeutics Advances with Sanofi in Phase 2 Trials
PremiumCompany Announcements
Kymera Therapeutics Shareholders Approve Key Governance ProposalsBulls Say, Bears Say
Bulls Say
Clinical Trials ExpansionSanofi has decided to expand the Phase 2 studies for IRAK4 degrader KT-474 in hidradenitis suppurativa and atopic dermatitis, which is seen as a positive signal for the drug's potential.
Regulatory AdvantagesExpanding the studies aims to accelerate timelines and inform regulatory trials, potentially improving the odds of success in future Phase 3 trials.
Safety And EfficacyThe decision to expand studies is informed by positive interim efficacy and safety data for KT-474, indicating a promising future for the treatment.
Bears Say
Adverse EffectsSentiment on KT-474's efficacy profile may become more negative if it seems like the current doses only have modest activity or need to be lowered due to adverse effects.
Clinical TrialsTimelines are pushed, neither the Ph2 HS or AD data will be in 1H25.
Product LaunchIf data from the HS and AD Ph2 POCs are delayed to 2H25/1H26, it's more likely to be 2028+ now for the product launch.
---
Ownership Overview
38.02% Insiders
33.02% Mutual Funds
13.93% Other Institutional Investors
15.03% Public Companies and
Individual Investors
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $9.60 and its highest was $48.70 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Currently, no data Available
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Aug 02, 2024 which is in 15 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on May 02, 2024. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.721 by $0.031.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Overvalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -$0.68.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 61,358,260 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.721. Following the earnings report the stock price went up 0.166%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Among the largest hedge funds holding Kymera Therapeutics’s share is Baker Bros Advisors LP. It holds Kymera Therapeutics’s shares valued at 241M.
---
Kymera Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.78 (-8.67% Downside)
$42.78 (-8.67% Downside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 518.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $90.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.01%
12-Months-Change
Fundamentals
Return on Equity
-26.35%
Trailing 12-Months
Asset Growth
41.43%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
---
KYMR Earnings Call
Q1 2024
0:00 / 0:00
---
KYMR Stock 12 Month Forecast
Average Price Target
$42.78
▼(-8.67% Downside)
Technical Analysis
Best Analysts Covering KYMR
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+43.33%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +43.33% per trade.
---